InnoCare Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

InnoCare Pharma wird ein jährliches Gewinn- und Umsatzwachstum von 26% bzw. 26.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 28.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -10.8% betragen.

Wichtige Informationen

18.7%

Wachstumsrate der Gewinne

23.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	40.0%
Wachstumsrate der Einnahmen	26.7%
Zukünftige Eigenkapitalrendite	-8.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	03 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report

Aug 22

Recent updates

Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%

Sep 13

Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report

Aug 22

Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?

Apr 11

Is InnoCare Pharma (HKG:9969) A Risky Investment?

Jan 25

Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt

Sep 05

InnoCare Pharma (HKG:9969) Is Using Debt Safely

Apr 30

Gewinn- und Umsatzwachstumsprognosen

SEHK:9969 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1,833	-274	439	-427	8
12/31/2025	1,325	-525	340	-543	8
12/31/2024	949	-602	N/A	-391	7
6/30/2024	781	-471	-835	-638	N/A
3/31/2024	715	-761	-832	-595	N/A
12/31/2023	739	-631	-920	-665	N/A
9/30/2023	721	-584	-759	-541	N/A
6/30/2023	757	-867	-817	-607	N/A
3/31/2023	696	-781	-716	-507	N/A
12/31/2022	625	-887	-861	-491	N/A
9/30/2022	503	-987	-888	-508	N/A
6/30/2022	1,187	-296	-229	150	N/A
3/31/2022	1,111	-78	-226	117	N/A
12/31/2021	1,043	-65	-4	167	N/A
9/30/2021	982	60	49	239	N/A
6/30/2021	102	-266	-464	-258	N/A
3/31/2021	52	-329	-444	-215	N/A
12/31/2020	1	-391	-424	-173	N/A
9/30/2020	1	-1,853	-393	-148	N/A
6/30/2020	1	-2,155	-320	-137	N/A
3/31/2020	1	-2,148	-237	-108	N/A
12/31/2019	1	-2,141	-155	-80	N/A
9/30/2019	2	-742	-43	-30	N/A
6/30/2019	2	-592	-22	-17	N/A
3/31/2019	2	-571	-30	-18	N/A
12/31/2018	2	-550	-38	-18	N/A
12/31/2017	0	-342	N/A	-49	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 9969 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 9969 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 9969 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 9969Die Einnahmen des Unternehmens (26.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (7.4% pro Jahr).

Hohe Wachstumseinnahmen: 9969Die Einnahmen des Unternehmens (26.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 9969 wird voraussichtlich in 3 Jahren unrentabel sein.

InnoCare Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus estimates of losses per share improve by 12%

Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report

Consensus revenue estimates decrease by 16%

InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023

Consensus EPS estimates upgraded to CN¥0.38 loss

No longer forecast to breakeven

Recent updates

InnoCare Pharma Limited Announces Board and Committee Changes

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29%

InnoCare Pharma Limited Announces End of Phase 2 Meeting with the U.S. Food and Drug Administration Regarding the Clinical Development of Orelabrutinib for the Treatment of Multiple Sclerosis

Consensus estimates of losses per share improve by 12%

Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

InnoCare Pharma Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S

InnoCare Pharma Limited to Report First Half, 2024 Results on Aug 21, 2024

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

InnoCare Pharma Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China

InnoCare Pharma Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

First quarter 2024 earnings released: CN¥0.08 loss per share (vs CN¥0.007 loss in 1Q 2023)

Consensus revenue estimates decrease by 16%

Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates

InnoCare Pharma Limited to Report Q1, 2024 Results on May 14, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

InnoCare Pharma Limited Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China

Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load?

InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023

InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China

InnoCare Pharma Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA

New minor risk - Profitability

InnoCare Pharma Appoints Xin Fu as Chief Financial Officer

InnoCare Pharma Announces Latest Data of Oncology Pipelines Presented at the 65th Annual Meeting of ASH

Third quarter 2023 earnings released: CN¥0.062 loss per share (vs CN¥0.28 loss in 3Q 2022)

New minor risk - Profitability

InnoCare Pharma Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China

Innocare Pharma Limited Announces the Appointment of Dandan Dong as Independent Non-Executive Director

Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?

InnoCare Pharma Limited (SEHK:9969) commences an Equity Buyback Plan for 149,967,323 shares, representing 8.5% of its issued share capital, under the authorization approved on June 2, 2023.

InnoCare Pharma Limited (SEHK:9969) commences an Equity Buyback Plan for 149,967,323 shares, representing 8.5% of its issued share capital, under the authorization approved on June 2, 2023.

InnoCare Pharma Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib

InnoCare Announces Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology

Second quarter 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.24 loss in 2Q 2022)

Innocare Pharma Limited Announces Board Changes

InnoCare Pharma Limited to Report First Half, 2023 Results on Aug 30, 2023

Consensus EPS estimates upgraded to CN¥0.38 loss

Is InnoCare Pharma (HKG:9969) Using Too Much Debt?

First quarter 2023 earnings released: CN¥0.01 loss per share (vs CN¥0.08 loss in 1Q 2022)

No longer forecast to breakeven

Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?

No longer forecast to breakeven

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2022

InnoCare Pharma Limited Announces the Latest Clinical Result of FGFR Inhibitor Gunagratinib (ICP-192) for the Treatment of Cholangiocarcinoma Was Presented At 2023 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium

Is InnoCare Pharma (HKG:9969) A Risky Investment?

InnoCare Pharma Limited Announces Approval of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong

Now 27% undervalued

No longer forecast to breakeven

InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China

InnoCare Pharma Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore

Consensus revenue estimates increase by 12%

Third quarter 2022 earnings released: CN¥0.28 loss per share (vs CN¥0.17 profit in 3Q 2021)

Less than half of directors are independent

InnoCare Pharma Limited to Report Nine Months, 2022 Results on Nov 11, 2022

InnoCare Announces First Adolescent Patient Dosed in Clinical Trial of pan-TRK Inhibitor ICP-723 in China

Forecast to breakeven in 2024

InnoCare Pharma Limited has completed a Follow-on Equity Offering in the amount of CNY 2.672498 billion.

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China

InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China

InnoCare Pharma Limited Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA

InnoCare Pharma Limited Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA

Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt

No longer forecast to breakeven

No longer forecast to breakeven

InnoCare Pharma Announces the Acceptance of the Biologics License Application for Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong